ARTICLE IN PRESSTHE JOURNAL0UROLOGYCheck forAUA Guideline Articlewww.auajournals.ong/journal/juroupdatesEarly Detection of Prostate Cancer:AUA/SUO GuidelinePart l:Prostate Cancer ScreeningJohn T.Wei,1*Daniel Barocas,2 Sigrid Carlsson,3 Fergus Coakley,4 Scott Eggener,5 Ruth Etzioni,sSamson W.Fine,3 Misop Han,7 Sennett K.Kim,3 Erin Kirkby,3 Badrinath R.Konety,3 Martin Miner,10Kelvin Moses,2 Merel G.Nissenberg,11 Peter A.Pinto,12 Simpa S.Salami,1 Lesley Souter,13lan M.Thompson,14 and Daniel W.Lin15University of Michigan,Ann Arbor,Michigan2Vander bilt University,Nashville,TennesseeMemorial Sloan Kettering Cancer Center,New York,New YorkOregon Health and Science University,Portland,OregonUniversity of Chicago,Chicago,Nlinois5Fred Hutchinson Cancer Center,Seattle,Washington7Johns Hopkins University,Baltimore,MarylandBAmerican Urological Association,Linthicum,MarylandANina Health1Brown University,Providence,Rhode IslandNational Alliance of State Prostate Cancer Coalitions12National nstitues of Health,Bethesda,Maryland13Nomadic EBM Methodology14CHRISTUS Health15University of Washington,Seattle,WashingtonPurpose:The summary presented herein covers recommendations on the earlydetection of prostate cancer and provides a framework to facilitate clinicaldecision-making in the implementation of prostate cancer screening,biopsy,andfollow-up.This is Part I of a two-part series that focuses on prostate cancerscreening.Please refer to Part II for discussion of initial and repeat biopsies aswell as biopsy technique.Materials and Methods:The systematic review utilized to inform this guidelinewas conducted by an independent methodological consultant.The systematicreview was based on searches in Ovid MEDLINE and Embase and CochraneDatabase of Systematic Reviews (January 1,2000-November 21,2022).Searches were supplemented by reviewing reference lists of relevant articles.The AUA employs a 3-tiered strength of evidence system to underpin evidence-based guideline statements.The AUA nomenclature system explicitly linksstatement type to body of evidence strength,level of certainty,magnitude ofbenefit or risk/burdens,and the Panel's judgment regarding the balance betweenbenefits and risks/burdens.Results:The Early Detection of Prostate Cancer Panel developed evidence-andconsensus-based guideline statements to provide guidance in prostate cancerscreening,initial and repeat biopsy,and biopsy technique.Conclusions:Prostate-specific antigen (PSA)-based prostate cancer screening incombination with shared decision-making (SDM)is recommended.Current dataSubmitted April 10.2023:accepted April 12.2023:published 000.The complete unabridged version of the guideline is available at https://www.juology.com.This document is being printed as submitted.independent of standad editorial or peer review by the editors of Theoualof oog*Comespondence:Department of Uralogy.University of Michigan,1500 E Medical Center Drive,SPC 5330,3875TC.Ann Abor,M 48109-5330(包lephone:734-15300:email:jtwei@umich
